SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit

robot
Abstract generation in progress

Rosen Law Firm reminds purchasers of Soleno Therapeutics, Inc. (NASDAQ: SLNO) common stock between March 26, 2025, and November 4, 2025, that the lead plaintiff deadline to join a securities fraud lawsuit is May 5, 2026. The lawsuit alleges that Soleno made misleading statements regarding safety concerns and commercial viability of its DCCR treatment for Prader-Willi syndrome. Investors who purchased during this period may be entitled to compensation.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments